Advertisement

Topics

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma

20:00 EDT 16 May 2019 | AAAS

(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores.

Original Article: Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement